Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Teijin Pharma Licenses Bronchial Asthma Treatment from UK Company with Hopes to Boost Priority Field
September 27, 2012
- Nipro to Integrate Nipro Pharma to Strengthen Pharmaceutical Business
September 27, 2012
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
- Kyorin Files NDA for Asthma Treatment KRP-108 in Japan
September 26, 2012
- Janssen Pharmaceutical Files for Once-Monthly Schizophrenia Treatment in Japan
September 26, 2012
- Kyowa Pharmaceutical Voluntarily Recalls Allopurinol Tablets 100 mg
September 25, 2012
- Sanofi-Aventis Looks to Clinical Evidence to Differentiate Lantus from Rival
September 25, 2012
- Equa Tops Both GP, HP Markets in August: RepTrack Survey
September 24, 2012
- Most Top Drugstore Chains Plan to Continue Dispensing Point Services After October
September 24, 2012
- Prasugrel Achieves Primary Endpoint in Domestic PIII Trial, Expects to Submit NDA in FY2013: Daiichi Sankyo
September 24, 2012
- Novartis to File for Additional Indication for Lucentis in Japan within This Year
September 24, 2012
- Pfizer Preparing for Assault on Domestic Generic Drug Market with Help from Mylan
September 24, 2012
- MTPC Launches Simponi in Indonesia
September 21, 2012
- Nichi-Iko to Set Up New Sections in Sales, Development Divisions to Enhance Oncology Field
September 21, 2012
- Nippon Shinyaku Files for Additional Indication of Chronic Pain for Tramal Capsule
September 21, 2012
- Chugai Applies for Avastin for Recurrent Glioblastoma
September 21, 2012
- Astellas, KEK Announce Collaboration to Develop New Drugs for NTDs
September 21, 2012
- Intellim Establishes Local Office in South Korea, Set to Realize Asian Studies
September 20, 2012
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…